{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T18:02:45Z","timestamp":1776535365040,"version":"3.51.2"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autoantigen-specific regulatory immunity emerges in the spleen of mice recovering from experimental autoimmune uveitis (EAU), a murine model for human autoimmune uveoretinitis. This regulatory immunity provides induced tolerance to ocular autoantigen, and requires melanocortin 5 receptor (MC5r) expression on antigen presenting cells with adenosine 2 A receptor (A2Ar) expression on T cells. During EAU it is not well understood what roles MC5r and A2Ar have on promoting regulatory immunity. Cytokine profile analysis during EAU revealed MC5r and A2Ar each mediate distinct T cell responses, and are responsible for a functional regulatory immune response in the spleen. A2Ar stimulation at EAU onset did not augment this regulatory response, nor bypass the MC5r requirement to induce regulatory immunity. The importance of this pathway in human autoimmune uveitis was assayed. PBMC from uveitis patients were assayed for MC5r expression on monocytes and A2Ar on T cells, and comparison between uveitis patients and healthy controls had no significant difference. The importance for MC5r and A2Ar expression in EAU to promote the induction of protective regulatory immunity, and the expression of MC5r and A2Ar on human immune cells, suggests that it may be possible to utilize the melanocortin-adenosinergic pathways to induce protective immunity in uveitic patients.<\/jats:p>","DOI":"10.1038\/srep37790","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T10:34:05Z","timestamp":1480070045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["MC5r and A2Ar Deficiencies During Experimental Autoimmune Uveitis Identifies Distinct T cell Polarization Programs and a Biphasic Regulatory Response"],"prefix":"10.1038","volume":"6","author":[{"given":"Darren J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Preble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew W.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,25]]},"reference":[{"key":"BFsrep37790_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1001\/archopht.1962.00960030506014","volume":"68","author":"RW Darrell","year":"1962","unstructured":"Darrell, R. W., Wagener, H. P. & Kurland, L. T. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 68, 502\u2013514 (1962).","journal-title":"Arch Ophthalmol"},{"key":"BFsrep37790_CR2","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1016\/j.ophtha.2012.05.026","volume":"119","author":"DK Hwang","year":"2012","unstructured":"Hwang, D. K., Chou, Y. J., Pu, C. Y. & Chou, P. Epidemiology of uveitis among the Chinese population in Taiwan: a population-based study. Ophthalmology 119, 2371\u20132376, doi: 10.1016\/j.ophtha.2012.05.026 (2012).","journal-title":"Ophthalmology"},{"key":"BFsrep37790_CR3","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ajo.2008.09.014","volume":"146","author":"EB Suhler","year":"2008","unstructured":"Suhler, E. B., Lloyd, M. J., Choi, D., Rosenbaum, J. T. & Austin, D. F. Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol 146, 890\u2013896 e898, doi: 10.1016\/j.ajo.2008.09.014 (2008).","journal-title":"Am J Ophthalmol"},{"key":"BFsrep37790_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","volume":"111","author":"DC Gritz","year":"2004","unstructured":"Gritz, D. C. & Wong, I. G. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111, 491\u2013500, discussion 500 (2004).","journal-title":"Ophthalmology"},{"key":"BFsrep37790_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/bjo.2005.083725","volume":"91","author":"M Natkunarajah","year":"2007","unstructured":"Natkunarajah, M., Kaptoge, S. & Edelsten, C. Risks of relapse in patients with acute anterior uveitis. Br J Ophthalmol 91, 330\u2013334, doi: 10.1136\/bjo.2005.083725 (2007).","journal-title":"Br J Ophthalmol"},{"key":"BFsrep37790_CR6","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4049\/jimmunol.140.5.1490","volume":"140","author":"RR Caspi","year":"1988","unstructured":"Caspi, R. R. et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 140, 1490\u20131495 (1988).","journal-title":"J Immunol"},{"key":"BFsrep37790_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.2174\/1566524015666150731100318","volume":"15","author":"J Chen","year":"2015","unstructured":"Chen, J., Qian, H., Horai, R., Chan, C. C. & Caspi, R. R. Mouse Models of Experimental Autoimmune Uveitis: Comparative Analysis of Adjuvant-Induced vs Spontaneous Models of Uveitis. Curr Mol Med 15, 550\u2013557 (2015).","journal-title":"Curr Mol Med"},{"key":"BFsrep37790_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000119871","volume":"40","author":"RR Caspi","year":"2008","unstructured":"Caspi, R. R. et al. Mouse models of experimental autoimmune uveitis. Ophthalmic Res 40, 169\u2013174, doi: 10.1159\/000119871 (2008).","journal-title":"Ophthalmic Res"},{"key":"BFsrep37790_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1189\/jlb.0204114","volume":"77","author":"N Kitaichi","year":"2005","unstructured":"Kitaichi, N., Namba, K. & Taylor, A. W. Inducible immune regulation following autoimmune disease in the immune-privileged eye. J Leukoc Biol 77, 496\u2013502 (2005).","journal-title":"J Leukoc Biol"},{"key":"BFsrep37790_CR10","doi-asserted-by":"publisher","first-page":"8862","DOI":"10.1167\/iovs.11-8153","volume":"52","author":"DJ Lee","year":"2011","unstructured":"Lee, D. J. & Taylor, A. W. Following EAU recovery there is an associated MC5r-dependent APC induction of regulatory immunity in the spleen. Invest Ophthalmol Vis Sci 52, 8862\u20138867, doi: 10.1167\/iovs.11-8153 (2011).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep37790_CR11","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.4049\/jimmunol.1300182","volume":"191","author":"DJ Lee","year":"2013","unstructured":"Lee, D. J. & Taylor, A. W. Both MC5r and A2Ar Are Required for Protective Regulatory Immunity in the Spleen of Post-Experimental Autoimmune Uveitis in Mice. J Immunol 191, 4103\u20134111, doi: 10.4049\/jimmunol.1300182 (2013).","journal-title":"J Immunol"},{"key":"BFsrep37790_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1189\/jlb.3A1014-466RR","volume":"97","author":"DJ Lee","year":"2015","unstructured":"Lee, D. J. & Taylor, A. W. Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. J Leukoc Biol 97, 1101\u20131109, doi: 10.1189\/jlb.3A1014-466RR (2015).","journal-title":"J Leukoc Biol"},{"key":"BFsrep37790_CR13","first-page":"53","volume":"52","author":"AW Taylor","year":"2006","unstructured":"Taylor, A. W., Kitaichi, N. & Biros, D. Melanocortin 5 receptor and ocular immunity. Cell Mol Biol (Noisy-le-grand) 52, 53\u201359 (2006).","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"BFsrep37790_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.bbi.2007.11.001","volume":"22","author":"AW Taylor","year":"2008","unstructured":"Taylor, A. W. & Kitaichi, N. The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) therapy. Brain Behav Immun 22, 639\u2013646, doi: 10.1016\/j.bbi.2007.11.001 (2008).","journal-title":"Brain Behav Immun"},{"key":"BFsrep37790_CR15","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3109\/02713689208999545","volume":"11","author":"AW Taylor","year":"1992","unstructured":"Taylor, A. W., Streilein, J. W. & Cousins, S. W. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res 11, 1199\u20131206 (1992).","journal-title":"Curr Eye Res"},{"key":"BFsrep37790_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1042\/bj3310211","volume":"331","author":"JJ Buggy","year":"1998","unstructured":"Buggy, J. J. Binding of alpha-melanocyte-stimulating hormone to its G-protein-coupled receptor on B-lymphocytes activates the Jak\/STAT pathway. The Biochemical journal 331(Pt 1), 211\u2013216 (1998).","journal-title":"The Biochemical journal"},{"key":"BFsrep37790_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2174\/1568010043343606","volume":"3","author":"CW Lam","year":"2004","unstructured":"Lam, C. W. & Getting, S. J. Melanocortin receptor type 3 as a potential target for anti-inflammatory therapy. Curr Drug Targets Inflamm Allergy 3, 311\u2013315 (2004).","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"BFsrep37790_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1189\/jlb.0707463","volume":"84","author":"D Li","year":"2008","unstructured":"Li, D. & Taylor, A. W. Diminishment of alpha-MSH anti-inflammatory activity in MC1r siRNA-transfected RAW264.7 macrophages. J Leukoc Biol 84, 191\u2013198 (2008).","journal-title":"J Leukoc Biol"},{"key":"BFsrep37790_CR19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.intimp.2009.05.001","volume":"9","author":"DJ Lee","year":"2009","unstructured":"Lee, D. J., Biros, D. J. & Taylor, A. W. Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis. International immunopharmacology 9, 1079\u20131086 (2009).","journal-title":"International immunopharmacology"},{"key":"BFsrep37790_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1749-6632.2000.tb05389.x","volume":"917","author":"AW Taylor","year":"2000","unstructured":"Taylor, A. W., Yee, D. G., Nishida, T. & Namba, K. Neuropeptide regulation of immunity. The immunosuppressive activity of alpha-melanocyte-stimulating hormone (alpha-MSH). Ann N Y Acad Sci 917, 239\u2013247 (2000).","journal-title":"Ann N Y Acad Sci"},{"key":"BFsrep37790_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fimmu.2012.00190","volume":"3","author":"A Ohta","year":"2012","unstructured":"Ohta, A., Kini, R., Subramanian, M., Madasu, M. & Sitkovsky, M. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 3, 190, doi: 10.3389\/fimmu.2012.00190 (2012).","journal-title":"Front Immunol"},{"key":"BFsrep37790_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fimmu.2014.00304","volume":"5","author":"A Ohta","year":"2014","unstructured":"Ohta, A. & Sitkovsky, M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol 5, 304, doi: 10.3389\/fimmu.2014.00304 (2014).","journal-title":"Front Immunol"},{"key":"BFsrep37790_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000336183","volume":"51","author":"J Kruh","year":"2012","unstructured":"Kruh, J. & Foster, C. S. The philosophy of treatment of uveitis: past, present and future. Dev Ophthalmol 51, 1\u20136, doi: 10.1159\/000336183 (2012).","journal-title":"Dev Ophthalmol"},{"key":"BFsrep37790_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2015.07.001","volume":"61","author":"CS Foster","year":"2016","unstructured":"Foster, C. S. et al. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol 61, 1\u201317, doi: 10.1016\/j.survophthal.2015.07.001 (2016).","journal-title":"Surv Ophthalmol"},{"key":"BFsrep37790_CR25","doi-asserted-by":"crossref","unstructured":"Melcarne, L., Garcia-Iglesias, P. & Calvet, X. Management of NSAID-associated peptic ulcer disease. Expert Rev Gastroenterol Hepatol, 1\u201311, doi: doi: 10.1586\/17474124.2016.1142872 (2016).","DOI":"10.1586\/17474124.2016.1142872"},{"key":"BFsrep37790_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2217\/imt.12.134","volume":"5","author":"M Takeuchi","year":"2013","unstructured":"Takeuchi, M. A systematic review of biologics for the treatment of noninfectious uveitis. Immunotherapy 5, 91\u2013102, doi: 10.2217\/imt.12.134 (2013).","journal-title":"Immunotherapy"},{"key":"BFsrep37790_CR27","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.survophthal.2011.05.003","volume":"56","author":"K Durrani","year":"2011","unstructured":"Durrani, K. et al. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol 56, 474\u2013510, doi: 10.1016\/j.survophthal.2011.05.003 (2011).","journal-title":"Surv Ophthalmol"},{"key":"BFsrep37790_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/1744666X.2016.1166052","volume":"12","author":"A Maleki","year":"2016","unstructured":"Maleki, A., Meese, H., Sahawneh, H. & Foster, C. S. Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis. Expert Rev Clin Immunol, 1\u201312, doi: 10.1586\/1744666X.2016.1166052 (2016).","journal-title":"Expert Rev Clin Immunol"},{"key":"BFsrep37790_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1869-5760-3-64","volume":"3","author":"DS Chu","year":"2013","unstructured":"Chu, D. S. et al. Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect 3, 64, doi: 10.1186\/1869-5760-3-64 (2013).","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"BFsrep37790_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/sj.bjp.0703532","volume":"131","author":"SG Apasov","year":"2000","unstructured":"Apasov, S. G. et al. Study of A(2A) adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A(2A) receptor-unrelated lymphotoxicity. Br J Pharmacol 131, 43\u201350, doi: 10.1038\/sj.bjp.0703532 (2000).","journal-title":"Br J Pharmacol"},{"key":"BFsrep37790_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","volume":"117","author":"SS Pujari","year":"2010","unstructured":"Pujari, S. S. et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117, 356\u2013365, doi: doi: 10.1016\/j.ophtha.2009.06.060 (2010).","journal-title":"Ophthalmology"},{"key":"BFsrep37790_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10238-015-0345-6","volume":"16","author":"M Prete","year":"2016","unstructured":"Prete, M., Dammacco, R., Fatone, M. C. & Racanelli, V. Autoimmune uveitis: clinical, pathogenetic, and therapeutic features. Clin Exp Med 16, 125\u2013136, doi: 10.1007\/s10238-015-0345-6 (2016).","journal-title":"Clin Exp Med"},{"key":"BFsrep37790_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2008.01.004","volume":"250","author":"K Mahnke","year":"2007","unstructured":"Mahnke, K., Bedke, T. & Enk, A. H. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cellular immunology 250, 1\u201313, doi: 10.1016\/j.cellimm.2008.01.004 (2007).","journal-title":"Cellular immunology"},{"key":"BFsrep37790_CR34","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.4049\/jimmunol.1401434","volume":"194","author":"S Ring","year":"2015","unstructured":"Ring, S. et al. Regulatory T cell-derived adenosine induces dendritic cell migration through the Epac-Rap1 pathway. J Immunol 194, 3735\u20133744, doi: 10.4049\/jimmunol.1401434 (2015).","journal-title":"J Immunol"},{"key":"BFsrep37790_CR35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1365-3083.2005.01565.x","volume":"61","author":"GN Andersen","year":"2005","unstructured":"Andersen, G. N. et al. Quantitative measurement of the levels of melanocortin receptor subtype 1, 2, 3 and 5 and pro-opio-melanocortin peptide gene expression in subsets of human peripheral blood leucocytes. Scand J Immunol 61, 279\u2013284, doi: 10.1111\/j.1365-3083.2005.01565.x (2005).","journal-title":"Scand J Immunol"},{"key":"BFsrep37790_CR36","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.4049\/jimmunol.179.8.5228","volume":"179","author":"B Zhu","year":"2007","unstructured":"Zhu, B. et al. CD11b\u2009+\u2009Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 179, 5228\u20135237 (2007).","journal-title":"J Immunol"},{"key":"BFsrep37790_CR37","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.4049\/jimmunol.1100403","volume":"187","author":"B Zhu","year":"2011","unstructured":"Zhu, B. et al. Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J Immunol 187, 2418\u20132432, doi: 10.4049\/jimmunol.1100403 (2011).","journal-title":"J Immunol"},{"key":"BFsrep37790_CR38","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1586\/1744666X.2014.915739","volume":"10","author":"S Muller-Haegele","year":"2014","unstructured":"Muller-Haegele, S., Muller, L. & Whiteside, T. L. Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Rev Clin Immunol 10, 897\u2013914, doi: 10.1586\/1744666X.2014.915739 (2014).","journal-title":"Expert Rev Clin Immunol"},{"key":"BFsrep37790_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1189\/jlb.0908577","volume":"86","author":"S Hatfield","year":"2009","unstructured":"Hatfield, S., Belikoff, B., Lukashev, D., Sitkovsky, M. & Ohta, A. The antihypoxia-adenosinergic pathogenesis as a result of collateral damage by overactive immune cells. Journal of leukocyte biology 86, 545\u2013548, doi: 10.1189\/jlb.0908577 (2009).","journal-title":"Journal of leukocyte biology"},{"key":"BFsrep37790_CR40","doi-asserted-by":"crossref","unstructured":"Clemson, C. M., Yost, J. & Taylor, A. W. The Role of Alpha-MSH as a Modulator of Ocular Immunobiology Exemplifies Mechanistic Differences between Melanocortins and Steroids. Ocul Immunol Inflamm, 1\u201311, doi: 10.3109\/09273948.2015.1092560 (2016).","DOI":"10.3109\/09273948.2015.1092560"},{"key":"BFsrep37790_CR41","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3389\/fimmu.2015.00654","volume":"6","author":"AL Perdigoto","year":"2016","unstructured":"Perdigoto, A. L., Chatenoud, L., Bluestone, J. A. & Herold, K. C. Inducing and Administering Tregs to Treat Human Disease. Front Immunol 6, 654, doi: 10.3389\/fimmu.2015.00654 (2016).","journal-title":"Front Immunol"},{"key":"BFsrep37790_CR42","doi-asserted-by":"crossref","unstructured":"Bluestone, J. A. et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 7, 315ra189, doi: 10.1126\/scitranslmed.aad4134 (2015).","DOI":"10.1126\/scitranslmed.aad4134"},{"key":"BFsrep37790_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fimmu.2016.00037","volume":"7","author":"AW Taylor","year":"2016","unstructured":"Taylor, A. W. Ocular Immune Privilege and Transplantation. Front Immunol 7, 37, doi: 10.3389\/fimmu.2016.00037 (2016).","journal-title":"Front Immunol"},{"key":"BFsrep37790_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000099255","volume":"92","author":"AW Taylor","year":"2007","unstructured":"Taylor, A. W. Ocular immunosuppressive microenvironment. Chem Immunol Allergy 92, 71\u201385 (2007).","journal-title":"Chem Immunol Allergy"},{"key":"BFsrep37790_CR45","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/eye.2008.382","volume":"23","author":"AW Taylor","year":"2009","unstructured":"Taylor, A. W. Ocular immune privilege. Eye (London, England) 23, 1885\u20131889 (2009).","journal-title":"Eye (London, England)"},{"key":"BFsrep37790_CR46","first-page":"2010","volume":"40","author":"K Ohta","year":"1999","unstructured":"Ohta, K., Wiggert, B., Taylor, A. W. & Streilein, J. W. Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci 40, 2010\u20132018 (1999).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep37790_CR47","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1189\/jlb.72.5.946","volume":"72","author":"K Namba","year":"2002","unstructured":"Namba, K., Kitaichi, N., Nishida, T. & Taylor, A. W. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J Leukoc Biol 72, 946\u2013952 (2002).","journal-title":"J Leukoc Biol"},{"key":"BFsrep37790_CR48","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1076\/ceyr.16.9.900.5043","volume":"16","author":"AW Taylor","year":"1997","unstructured":"Taylor, A. W., Alard, P., Yee, D. G. & Streilein, J. W. Aqueous humor induces transforming growth factor-beta (TGF-beta)-producing regulatory T-cells. Curr Eye Res 16, 900\u2013908 (1997).","journal-title":"Curr Eye Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep37790.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37790","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37790.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:57:39Z","timestamp":1672887459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep37790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,25]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep37790"],"URL":"https:\/\/doi.org\/10.1038\/srep37790","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,25]]},"assertion":[{"value":"26 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AWT has been a consultant to Palatin Technologies, and Mallinckrodt Pharmaceuticals. All other authors have no relevant competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37790"}}